Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1381-1400 of 1,694 trials

Multiple Sclerosis: Masitinib Treatment Study

We are investigating whether the oral medication masitinib is effective and safe for people with primary or secondary progressive multiple sclerosis without relapses. This study compares masitinib to a placebo to evaluate its impact on various symptoms and overall health.

Multiple Sclerosis1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Cholangiocarcinoma: SIRT and Capecitabine Study

We are evaluating a new treatment combining radiation therapy and chemotherapy for patients with operable intrahepatic cholangiocarcinoma. This study aims to see if this combination helps improve treatment outcomes before surgery.

Intrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Generalized Anxiety Disorder: ITI-1284 Treatment Study

We are evaluating the safety and effectiveness of a new medication, ITI-1284, for people with Generalized Anxiety Disorder who haven't found relief with current treatments. This study compares ITI-1284 to a placebo to see how well it works.

Generalized Anxiety Disorder≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPsychiatry

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Rheumatoid Arthritis: Targeted Therapy vs. Triple Therapy

We are studying whether targeted therapies are more effective than a combination of three other medications for patients with rheumatoid arthritis who haven't responded to standard treatments. The trial also looks at safety and quality of life.

Rheumatoid ArthritisConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

COPD: Atorvastatin for Reducing Exacerbations

We are studying whether atorvastatin can help reduce flare-ups in smokers with chronic obstructive pulmonary disease. The trial also looks at how this medication may affect lung function and quality of life.

Chronic Obstructive Pulmonary Disease>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicinePulmonology

Multiple Sclerosis: IMU-838 Treatment Study

We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.

Relapsing-Remitting Multiple Sclerosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

HPV-Negative Head and Neck Cancer: PARP Inhibitor and Immunotherapy Study

We are investigating a new treatment combining a PARP inhibitor and immunotherapy for patients with HPV-negative head and neck cancer. The study aims to see how well this treatment works and its safety compared to standard options.

Oropharyngeal Squamous Cell CarcinomaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Alagille Syndrome: Long-Term Study of Livmarli

We are examining the long-term safety and effectiveness of Livmarli in patients with Alagille Syndrome. This study will help us understand how well the treatment works and its tolerability over time.

Alagille Syndrome>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyHepatologyInternal Medicine

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hypochondroplasia: Infigratinib for Growth

We are investigating whether infigratinib can help children aged 3 to 11 with hypochondroplasia grow taller and improve their overall health. The study will also look at the safety of this new treatment.

Hypochondroplasia>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Baricitinib for Children Hospitalized with COVID-19

We are studying how the medication baricitinib works in children aged 1 to under 18 years who are hospitalized with COVID-19. This research aims to ensure the safety and proper dosing for young patients.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Ovarian Cancer: Olaparib Maintenance Therapy

We are studying the effects of Olaparib as a maintenance treatment for patients with newly diagnosed advanced ovarian cancer. This trial aims to understand its safety and how it may improve patient outcomes.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Ovarian Cancer: Olaparib Treatment Study

We are investigating the effects of Olaparib in patients with recurrent ovarian cancer who do not have BRCA mutations. The goal is to see if it helps maintain treatment benefits after initial therapy and to understand its safety and effectiveness.

Recurrent Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Recurrent Ovarian Cancer: Olaparib vs. Chemotherapy

We are studying whether olaparib can help patients with recurrent ovarian cancer live longer without disease progression after surgery, compared to standard chemotherapy. The trial also looks at safety and quality of life.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Tardive Dyskinesia: Testing ADE513

We are studying a new medication to see if it helps reduce involuntary movements in people with moderate to severe tardive dyskinesia. The trial also looks at the safety and tolerability of this treatment.

Tardive Dyskinesia3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyPsychiatry

Rheumatoid Arthritis: Spironolactone Study

We are investigating whether spironolactone can help reduce symptoms in people with active rheumatoid arthritis. The study will also monitor safety and other health indicators.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

Corticobasal Syndrome: Glycerol Phenylbutyrate Study

We are investigating whether glycerol phenylbutyrate can lower nerve damage markers in patients with corticobasal syndrome. This study will also look at the safety and tolerability of the treatment.

Corticobasal Syndrome6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineNeurology